LLY, LILLY IS THIS STOCK PRICE SILLY?I hope you appreciated my rhyme.
So what to say about this.
One main trend line at the moment.
Big support incoming at 580 to 560 range.
Really big support at 108.
The lines in the middle (light green and red) are fairly weak and more likely short term targets.
I assume the long term targets will line up well with the gaps which are marked in orange.
Orange also on RSI, which is saying be careful.
Short term can take it up to 980 or so but I think the lower targets are more likely and we'll see the higher targets after trend breaks and before it starts to really drop.
However, there are a lot of possibilities that can occur.
The main possibility looks to be a chance of a move to 980, but more likely won't get there and might stick around 780.
I really have a hard time saying what this will do and when it will top out, I could tell you more if I watched this daily, but I don't.
This chart is long term price targets for the downside and the upside.
Given the single trend, you'll need a new chart as more develop, feel free to message if I haven't updated after some time.
I think that covers most everything.
Summary.
I think this stock is overvalued big time, but still has potential to keep seeing more upside in the short and mid term.
Lilly
LLY rides its success against obesity and diabetes LONGLLY shown on a daily chart has doubled in the past year with the introduction of new FDA
approved drugs into the market. It has but out a series of favorable earnings reports with
optimistic realistic guidance and glowing analysts' forecasts. It has done so without any volume
pumps and just keeps grinding higher. This is because it is in the shadows of big technology
stocks. Revenues consistently beat analysts' forecasts quarter after quarter.
Institutions add small lots trying to preserve the price for future buys without any
run-ups. I have done the same thing and I will continue to do so. While day trading
biotechnology penny stocks, LLY along with UNH, PFE, and AZN is where the profits are
parked for growth and compounding.
Eli Lilly, Bear Divergence and a Repeat Head & Shoulders PatternEli Lilly Oversold on the Monthly RSI.
RSI and MacD are both indicating bearish divergence.
Repeat on Head & Shoulders Pattern
Stock trading at 50x of earnings (forward P/E is 20), PEG ratio of 3.50! Price is 9x book value.
High Risk to Reward Ratio
3.8 to 1 with a large stop of $5.50
6:1 or better with a stop above the swing high
Target 1: $96
Target 2: $90
You could open a short now with a 5.5% stop loss, or you could wait for the H&S to complete itself.